Rebecca Shover

1 week ago | physiciansweekly.com | Rebecca Shover

On this week’s episode, Megan Georges, David Wiley, and Dr. Elizabeth Pino discuss disparities in rehabilitation care access for patients with violent penetrating injuries. Ms. Georges: Hi everyone. My name is Megan Georges. I am the data and research manager for the Violence Intervention Advocacy Program (VIAP) at Boston Medical Center.

2 weeks ago | physiciansweekly.com | Rebecca Shover

In this week’s episode, Dr. Tom Zaubler continues discussing how AI can expand access to behavioral healthcare and improve patient outcomes. Let’s say you’re a behavioral provider. You’re seeing a patient in a snapshot, which can be limiting. AI allows for a collection of data that is not limited to a snapshot of time. One reason that is so important is issues around safety.

2 weeks ago | physiciansweekly.com | Rebecca Shover

Stay connected to the latest news with Physician’s Weekly Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues. Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons. SUBSCRIBE NOW

3 weeks ago | physiciansweekly.com | Rebecca Shover

In this episode, Dr. Tom Zaubler discusses how AI can improve access to behavioral healthcare and give practitioners more time to spend with their patients. Hi, I’m Tom Zaubler. I’m a psychiatrist and chief medical officer at NeuroFlow. NeuroFlow is a technology company focused on creating an infrastructure to improve access to behavioral healthcare in various settings. We do that in a number of methods, and I’ll describe them today. We work with payers, providers, the VA, and many other clients.

4 weeks ago | physiciansweekly.com | Rebecca Shover

Researchers found changes in 57 metabolites among patients with tardive dyskinesia, indicating their potential impact on disease development and as a biomarker. Many recent studies on tardive dyskinesia have focused on treatment, including deep brain stimulation and vesicular monoamine transporter type 2 inhibitors. A study published in Schizophrenia Bulletin takes a step back, looking at metabolomics and potential diagnostic biomarkers for the condition.